Summary
We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette–Guérin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA– DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Akaza, H., Hinotsu, S., Aso, Y., Kakizoe, T. & Koiso, K. (1995). Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer, 75: 552–559.
Boyum, A. J. (1968). Isolation of mononuclear cells and granulocytes from human blood. Scan J Clin Lab Invest, 21: 77–79.
Carballido, J., Alvarez Mon, M., Olivier, C. & Molto, L. (1990a). Immunotherapy of urothelial neoplasms. Experimental and clinical implications of alpha interferon. Arch Esp Urol, 43: 149–158.
Carballido, J., Alvarez Mon, M., Solovera, O. J., Menendez Ondina, L. & Durantez, A. (1990b). Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol, 143: 29–33.
De Reijke, T. M., De Boer, E. C., Kurth, K. H. & Schamhart, D. H. (1996). Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol, 155: 477–482.
Erton, M. & Ilker, Y. Akdas (1996). Carcinoma in situ and treatment options. Int Urol Nephrol 28: 33–42.
Esrig, D., Freeman, J., Stein, J. & Skinner, D. (1997). Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol, 15: 154–160.
Hermann, G. G., Petersen, K. R., Steven, K. & Zeuthen, J. (1990). Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol, 10: 311–320.
Hurle, R., Losa, A., Ranieri, A., Graziotti, P. & Lembo, A. (1996). Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol, 156: 1602–1605.
Jackson, A. M., Alexandroff, A. B., McIntyre, M., Esuvaranathan, K., James, K. & Chisholm, G. D. (1994). Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol, 47: 309–312.
Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S., Chisholm, G. D. & James, K. (1995). Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol, 99: 369–375.
Kaempfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nussinovich, R. & Shapiro, A. (1996). Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol, 14: 1778–1786.
Koss, L. M. (1973). Tumours of the urinary bladder. In Atlas of Tumour Pathology, Armed Forces Institute of Pathology(eds) pp ???
Kurth, K. (1997). Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives. Eur Urol, 31: 10–19.
Kurth, K., Tunn, U., Ay, R., Schroder, F., Pavone-Macaluso, M., Debruyne, F., ten Kate, F., de Pauw, M. & Sylvester, R. (1997). Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158: 378–384.
Lamm, D. L. & Torti, F. M. (1996). Bladder cancer, 1996. CA Cancer J Clin, 46: 93–112.
Lapham, R., Ro, J., Staerkel, G. & Ayala, A. (1997). Pathology of transitional cell carcinoma of the bladder and its clinical implications. Semin Surg Oncol, 13: 307–318.
Larson, E. L., Iscove, N. N. & Coutinho, A. (1980). Two distinct factors are required for induction of T-cell growth. Nature, 283: 664–666.
Mack, D. & Frick, J. (1995). Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology, 45: 958–961.
Madsen, M., Johnsen, H. E., Hansen, P. W. & Christiansen, S. E. (1980). Isolation of human T and B lymphocytes by E-rosette gradient centrifugation. Characterization of the isolated sub-populations. J Immunol Methods, 33: 323–336.
Maes, H., Taper, H. & Cocito, C. (1995). Alteration of the immune response during cancer development and prevention by administration of a mycobacterial antigen. Scand J Immunol 41: 53–64.
Molto, L., Alvarez-Mon, M., Carballido, J., Olivier, C., Gimeno, F. & Manzano, L. (1995). Use of intracavitary interferon alpha 2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer 75: 1720–2726.
Molto, L., Carballido, J., Manzano, L., Reyes, E., Olivier, C. & Alvarez-Mon, M. (1997). Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br J Cancer, 75: 1849–1853.
Nadler, R. B., Catalona, W. J., Hudson, M. A. & Ratliff, T. L. (1994). Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol, 152: 367–373.
Nicks, M., Otto, M., Busova, B. & Stefanovic, J. (1990). Quantification of proliferative and suppressive responses of human T lymphocytes following ConA stimulation. J Immunol Methods 126: 263–271.
O’Donnell, M. A. & DeWolf, W. C. (1995). Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am, 4: 189–202.
Pansadoro, V., Emiliozzi, P., Defidio, L., Donadio, D., Florio, A., Maurelli, S., Lauretti, S. & Sternberg, C. N. (1995). Bacillus Calmette–Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol, 154: 2054–2058.
Patard, J. J., Chopin, D. K. & Boccon Gibod, L. (1993). Mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 11: 165–168.
Picker, L. J., Terstappen, LWMM, Rott, L. S., Streeter, P. R., Stein, H. & Butcher, E. C. (1990). Differential expression of homing-associated adhesion molecules by T cell subsets in man. J Immunol, 145: 3247–3255.
Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. & Smyth, J. F. (1992). Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147: 1636–1642.
Pryor, K., Goddard, J., Goldstein, D., Stricker, P., Russell, P., Golovsky, D. & Penny, R. (1995). Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer, 71: 801–807.
Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. & Catalona, W. J. (1993). T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol, 150: 1018–1023.
Rosenbaum, R. S., Park, M. C. & Fleischmann, J. (1996). Intravesical bacille Calmette-Guerin therapy for muscle invasive bladder cancer. Urology, 47: 208–211.
Satoh, M., Seki, S., Hashimoto, W., Ogasawara, K., Kobayashi, T., Kumagai, K., Matsuno, S. & Takeda, K. (1996). Citotoxic γδ or αβ T cells with a Natural Killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol, 157: 3886–3892.
Takashi, M., Wakai, K., Ohno, Y., Murase, T. & Miyake, K. (1995). Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol, 27: 723–733.
Thanhauser, A., Bohle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H. D. & Ulmer, A. J. (1995). The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother, 40: 103–108.
Turner, J. & Dockrell, H. M. (1996). Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology, 87: 339–342.
Verhagen, A., Mackay, I. R., Rowley, M. & Tymms, M. (1990). Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul, 9: 325–333.
Walker, P. R., Ohteki, T., Lopez, J. A., MacDonald, H. R. & Maryanski, J. L. (1995). Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response. J Immunol, 155: 3443–3452.
Witjes, J. (1997). Current recommendations for the management of bladder cancer. Drug therapy. Drugs, 53: 404–414.
Zlotta, A., Drowart, A., van Vooren, J. P., Simon, J., Schulman, C. C. & Huygen, K. (1994). Evolution of cellular and humoral response against tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer. Acta Urol Belg, 62: 63–68.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Reyes, E., Carballido, J., Manzano, L. et al. The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. Br J Cancer 79, 1162–1167 (1999). https://doi.org/10.1038/sj.bjc.6690185
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690185
